Browsing by Author Schadendorf, Dirk

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 13 of 13
Issue DateTitleAuthor(s)Citation
2017Activating CYSLTR2 and PLCB4 Mutations in Primary Leptomeningeal Melanocytic TumorsBuckland, Michael; Scolyer, Richard; Gessi, M; Griewank, Klaus; Koelsche, Christian; Moller, Inga; Murali, Rajmohan; Pietsch, T; Schadendorf, Dirk; Sucker, Antje; van de Nes, Johannes; School of Medical Sciences: Brain and Mind Centre; Central Clinical School: PathologyActivating CYSLTR2 and PLCB4 Mutations in Primary Leptomeningeal Melanocytic Tumors, Journal of Investigative Dermatology, vol.137, 9, 2017,pp 2033-2035
2012Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF InhibitionLong, Georgina; Busam, Klaus; Carvajal, Richard; Dummer, R; Egberts, Friederike; Goldinger, Simone; Hauschild, A; Hillen, Uwe; Kashani-Sabet, Mohammed; Lacouture, Mario; Livingstone, Elisabeth; McArthur, Grant A.; Schadendorf, Dirk; Scherag, Andre; Sucker, Antje; Zimmer, Lisa; Central Clinical School: The Sydney Cancer CentreAtypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition, Journal of Clinical Oncology, vol.30, 19, 2012,pp 2375-2383
2015Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaCarlino, Matteo; Long, Georgina; Chiarion-Sileni, Vanna; Cowey, C. Lance; Dummer, R; et al, Various; Gonzalez, Rene; Grob, Jean-Jacques; Lao, Christopher; Larkin, James; Schadendorf, Dirk; Smylie, Michael; Western Clinical School: Medicine (Westmead); Central Clinical School: The Sydney Cancer CentreCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, The New England Journal of Medicine, vol.373, 1, 2015,pp 23-34
2014Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future ProspectsScolyer, Richard; Thompson, John; Flaherty, Keith; Griewank, Klaus; Murali, Rajmohan; Schadendorf, Dirk; Central Clinical School: Pathology; Central Clinical School: SurgeryGenetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects, Journal of the National Cancer Institute, vol.106, 2, 2014,pp 1-17
2014Genetic and clinico-pathologic analysis of metastatic uveal melanomaHaydu, Lauren; Kakavand, Hojabr; Scolyer, Richard; Thompson, John; Asher, Marina; Griewank, Klaus; Hillen, Uwe; Moll, Iris; Murali, Rajmohan; Schadendorf, Dirk; Schilling, Bastian; Sucker, Antje; van de Nes, Johannes; Zimmer, Lisa; Central Clinical School: Surgery; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Central Clinical School: Pathology; Central Clinical School: SurgeryGenetic and clinico-pathologic analysis of metastatic uveal melanoma, Modern Pathology, vol.27, 2, 2014,pp 175-183
2010Genetic and morphologic features for melanoma classificationMcCarthy, Stanley; Scolyer, Richard; Barnhill, Raymond; Bauer, Jurgen; Boris, Bastian; Broekaert, Sigrid; Busam, Klaus; Cochran, Alistair; Cook, Martin; Elder, David E; Garbe, Claus; Mihm, Martin; Okamoto, Ichiro; Roy, Ritu; Schadendorf, Dirk; Spatz, Alan; van den Oord, Joost; Central Clinical School: Inst. of Anatomical Pathology RPAH; Central Clinical School: PathologyGenetic and morphologic features for melanoma classification, Pigment Cell & Melanoma Research, vol.23, 6,pp 763-770
2015Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanomaLong, Georgina; Amonkar, Mayur M; Bondarenko, Igor; de Braud, Filippo; et al, Various; Garbe, Claus; Gogas, Helen; Grob, Jean-Jacques; Lebbe, Celeste; Levchenko, Evgeny; Schadendorf, Dirk; Stroyakovskiy, Daniil; Central Clinical School: The Sydney Cancer CentreHealth-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma, European Journal of Cancer, vol.51, 7, 2015,pp 833-840
2017Health-related quality of life results from the phase III CheckMate 067 studyLong, Georgina; Chiarion-Sileni, Vanna; Cowey, C; et al, Various; Gonzalez, R; Grob, Jean-Jacques; Hodi, F. Stephen; Larkin, James; Rutkowski, Piotr; Schadendorf, Dirk; Wolchok, Jedd D.; Northern Clinical School: MedicineHealth-related quality of life results from the phase III CheckMate 067 study, European Journal of Cancer, vol.82, N/A, 2017,pp 80-91
2014Incidence of New Primary Melanomas After Diagnosis of Stage III and IV MelanomaHaydu, Lauren; Kefford, Richard (Rick); Long, Georgina; Menzies, Alexander Maxwel; Scolyer, Richard; Thompson, John; Schadendorf, Dirk; Zimmer, Lisa; Central Clinical School: Surgery; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Medicine; Central Clinical School: Pathology; Central Clinical School: SurgeryIncidence of New Primary Melanomas After Diagnosis of Stage III and IV Melanoma, Journal of Clinical Oncology, vol.32, 8, 2014,pp 816-823
2017Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression Analysis of 2 Phase 3 Clinical TrialsLong, Georgina; Atkinson, V; Dummer, R; et al, Various; Grob, Jean Jacques; Larkin, James; Márquez-Rodas, Ivan; McNeil, Catriona M.; Robert, Caroline; Schadendorf, Dirk; Schmidt, Henrik; Weber, Jeffrey; Northern Clinical School: MedicineNivolumab for Patients With Advanced Melanoma Treated Beyond Progression Analysis of 2 Phase 3 Clinical Trials, JAMA Oncology, vol.3, 11, 2017,pp 1511-1519
2017Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaCarlino, Matteo; Long, Georgina; Chiarion-Sileni, Vanna; Cowey, C; et al, Various; Gonzalez, Rene; Grob, Jean-Jacques; Lao, Christopher; Rutkowski, Piotr; Schadendorf, Dirk; Wagstaff, John; Wolchok, Jedd D.; Western Clinical School: Medicine (Westmead); Northern Clinical School: MedicineOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma, New England Journal of Medicine, vol.377, 14, 2017,pp 1345-1356
2015Systemic therapies for melanoma brain metastases: which drug for whom and when?Long, Georgina; Ramanujam, Sangeetha; Schadendorf, Dirk; Central Clinical School: The Sydney Cancer CentreSystemic therapies for melanoma brain metastases: which drug for whom and when?, Chinese Clinical Oncology, vol.4, 2, 2015,pp 25-N/A
2017Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasisLong, Georgina; Madore, Jason; Scolyer, Richard; Ahern, Elizabeth; Bald, Tobias; Barkauskas, Deborah; Boyle, Glen M; Chitsazan, Arash; Holzel, Michael; Huntington, Nicholas; Landsberg, Jennifer; Ngiow, Shin Foong; Rautela, Jai; Reinhardt, Julia; Schadendorf, Dirk; Smyth, Mark J; Young, Arabella; Northern Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: PathologyTargeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis, Cancer Research, vol.77, 17, 2017,pp OF1-OF13